Evidence map›Paper›PMID 36794507›Full record

ArticleHaematologica2023

Favorable pharmacokinetic and pharmacodynamic properties of gilteritinib in cerebrospinal fluid: a potential effective treatment in relapsing meningeal acute myeloid leukemia

Nicolas Vignal, Loïs Kelly, Etienne Lengline, Aurélie Cabannes-Hamy, Justine Siavellis, David Ghez, Hélène Sauvageon, Thorsten Braun, Evelyne Jacqz-Aigrain, Milena Kohn and 5 more

Open access · goldAbstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Haematologica, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Disease course ofHaematologica · 2026
    Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Nicolas VignalAP-HP, Hôpital Saint-Louis, Department of Pharmacology, Paris, France; INSERM U976, Université Paris Cité, Paris.
Loïs KellyINSERM U944, Université Paris-Cité, Paris.
Etienne LenglineAP-HP, Hôpital Saint-Louis, Department of Haematology, Paris.
Aurélie Cabannes-HamyCH Versailles, Department of Haemato-Oncology, Versailles.
Justine SiavellisAP-HP, Hôpital Avicenne, Department of Haematology, Paris.
David GhezIGR, Department of Haematology, Villejuif.
Hélène SauvageonAP-HP, Hôpital Saint-Louis, Department of Pharmacology, Paris, France; INSERM U976, Université Paris Cité, Paris.
Thorsten BraunAP-HP, Hôpital Avicenne, Department of Haematology, Paris.
Evelyne Jacqz-AigrainAP-HP, Hôpital Saint-Louis, Department of Pharmacology, Paris.
Milena KohnCH Versailles, Department of Haemato-Oncology, Versailles.
Philippe RousselotCH Versailles, Department of Haemato-Oncology, Versailles.
Alexandre PuissantINSERM U944, Université Paris-Cité, Paris.
Emmanuel RaffouxAP-HP, Hôpital Saint-Louis, Department of Haematology, Paris.
Samia MourahAP-HP, Hôpital Saint-Louis, Department of Pharmacology, Paris, France; INSERM U976, Université Paris Cité, Paris.
Lauriane GoldwirtAP-HP, Hôpital Saint-Louis, Department of Pharmacology, Paris, France; INSERM U976, Université Paris Cité, Paris. lauriane.goldwirt@aphp.fr.
Inserm · FRAssistance Publique – Hôpitaux de Paris · FRLaboratoire d'études sur les monothéismes · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Aniline CompoundsLeukemia, Myeloid, Acutefms-Like Tyrosine Kinase 3HumansMutationPyrazinesTreatment OutcomeAniline CompoundsFLT3 protein, humanfms-Like Tyrosine Kinase 3gilteritinibPyrazines

Identifiers

PMID36794507
PMCPMC10483363
OpenAlexW4321004085

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.